Public Health Expertise has extensive experience in the redaction and submission of health technology assessment dossiers in oncology, rares-diseases, endocrinology and infectiology. Former French High Health Authority (HAS) and pricing comittee members of the team allow for a global support in market access strategy and clinical experts interaction for drugs and medical devices.
PHE is the most experienced company in France for the submission of cost-effectiveness results in view of regulatory health technology assesment, including core models design and programming and smart and active adaptations. Our expertise in the methods and processes required to provide high-quality, robust and up to date results to decision makers, as well as internal medical skills allow us to provide global management of these projects.
Public Health Expertise has extensive experience in developping simulation models in various therapeutic areas and is recognised as an expert team, able to interpret and implement real-life data, clinical-trials based evidence, and clinical experts opinions into state-of-the-art mathematical models. By forecasting diseases burden, modelling studies support public affairs strategy in the long term.
Using strong knowledge of French medico-administrative databases, technical expertise in data analysis, statistics and neural networks and internal medical skills, Public Health Expertise conducts statistical studies in the field of healthcare and life sciences. Our experience includes analysis of medical registries, insurance claims databases and clinical trials results, as well as indirect treatment comparisons (network meta-analyses).
Public Health Expertise has developped methods for assessing organizational changes in partnership with experts in disease management programs implementation. Our evaluations are specifically suited to the project schemes and cover all levels of the healthcare system (practitioners network, hospital service, hospital/regional/national management), allowing for real-world valorization of the programs, thus ensuring the sustainability of their financing.
French National Cancer Institute (INCa) published the report on the study led by PHE, assessing modalities of organised screening for colorectal cancer. For this study, we developed a disease model …
PHE recently obtained an access and certification from the CNAMTS to the EGB database (Echantillon Généraliste des Bénéficiaires), with the aim of developing a predictive tool based on medico-administrative data. …
PHE will be present at ISPOR Europe 2018 held in Barcelona from 12/10 to 14/10. Poster presentation PCN240: ALL-COMERS VS. BIOMARKER BASED PATIENT SELECTION FOR BIOTHERAPIES IN ONCOLOGY: IMPACT ON …
How can we help?
Leave us your email, we will come back to you quickly.
